Company intelligence
Cruxx
Placing MedTech Pioneers in Transformative Roles to Help us Live Longer Healthier Lives.
About Cruxx
Cruxx places MedTech pioneers in transformative roles, to help us live longer, healthier lives. We connect visionary talent with leading companies shaping the future of healthcare innovation. We focus on placing leadership and innovators who are ready to push the boundaries of medical technology and help turn today’s ideas into tomorrow’s life-changing realities. At Cruxx, we don’t just find talent—we solve problems. We are changemakers, We are Purposeful, We are Impactful and We are relentless in our pursuit This is Cruxx.
Verified activity
Signals from Cruxx
10 published signals
Presence & Recognition
Cruxx published a full conversation with CEO of Kandu Leo Petrossian on Crux of Neuro.
Reported by Liz Moyles
Presence & Recognition
Cruxx hosted a full conversation with CEO of Kandu Leo Petrossian on Crux of Neuro.
Reported by Liz Moyles
Legal & Regulatory
Cruxx announced that in July, Chad Bouton, PhD, CEO Neuvotion, and collaborators published their double neural bypass work in Nature Medicine.
Reported by Liz Moyles
Legal & Regulatory
Cruxx announced that Paradromics, led by Matt Angle, received an FDA approval letter allowing its investigational Connexus BCI to connect with compatible laptops, tablets and phones within its Connect-One study.
Reported by Liz Moyles
Legal & Regulatory
Cruxx announced a second FDA Breakthrough Device Designation for Brain Interchange™, this time for communication, enabling people with non-progressive quadriplegia to control a computer cursor through thought alone.
Reported by Liz Moyles
Legal & Regulatory
Cruxx announced that Chinese BCI company WE-LINKING raised more than RMB100 million, approximately $14M, to advance its implantable platform.
Reported by Liz Moyles
Presence & Recognition
Cruxx produced a one-minute extract from the full conversation featuring Leo Petrossian and Cruxx CEO Liz Moyles.
Reported by Liz Moyles
Operations & Supply
Cruxx has its own manufacturing business supplying electrodes and implant components to other neurotechnology companies.
Reported by Liz Moyles
Legal & Regulatory
Cruxx announced its second FDA Breakthrough Device Designation for Brain Interchange™, which is now designated for stroke motor rehabilitation and communication for non-progressive quadriplegia.
Reported by Liz Moyles
Capital & Finance
Cruxx is raising its next funding round to advance the clinical programme.
Reported by Liz Moyles